| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 16/03/2009 | 11:00 | Edgar (US Regulatory) | Notice of Effectiveness (EFFECT) | AMEX:SYI | Synvista Therapeutics, |
| 12/03/2009 | 18:48 | Edgar (US Regulatory) | Post-Effective Amendment to Registration Statement (POS AM) | AMEX:SYI | Synvista Therapeutics, |
| 12/03/2009 | 11:03 | Edgar (US Regulatory) | Post-Effective Amendment to an S-8 filing (S-8 POS) | AMEX:SYI | Synvista Therapeutics, |
| 09/03/2009 | 17:25 | Edgar (US Regulatory) | Withdrawal of Registration Statement (RW) | AMEX:SYI | Synvista Therapeutics, |
| 09/03/2009 | 17:24 | Edgar (US Regulatory) | -National Securities Exchange Report the Removal from listing and reg. of matured,redeemed or retired securities (25) | AMEX:SYI | Synvista Therapeutics, |
| 26/02/2009 | 19:00 | Edgar (US Regulatory) | Current report filing (8-K) | AMEX:SYI | Synvista Therapeutics, |
| 24/02/2009 | 22:15 | PR Newswire (US) | Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE | AMEX:SYI | |
| 28/01/2009 | 22:00 | PR Newswire (US) | Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update | AMEX:SYI | |
| 12/01/2009 | 14:30 | PR Newswire (US) | Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium | AMEX:SYI | |
| 24/12/2008 | 19:24 | PR Newswire (US) | Synvista Notified by NYSE Alternext of Continued Listing Standards Non-Compliance | AMEX:SYI | |
| 16/12/2008 | 14:30 | PR Newswire (US) | Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline | AMEX:SYI | |
| 15/12/2008 | 14:30 | PR Newswire (US) | Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis | AMEX:SYI | |
| 03/12/2008 | 22:26 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | AMEX:SYI | Synvista Therapeutics, |
| 19/11/2008 | 15:43 | PR Newswire (US) | Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit | AMEX:SYI | Synvista Therapeutics, |
| 14/11/2008 | 21:57 | Edgar (US Regulatory) | Quarterly Report (10-Q) | AMEX:SYI | Synvista Therapeutics, |
| 11/11/2008 | 14:30 | PR Newswire (US) | Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA M | AMEX:SYI | Synvista Therapeutics, |
| 10/11/2008 | 17:57 | PR Newswire (US) | Synvista Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference | AMEX:SYI | Synvista Therapeutics, |
| 10/11/2008 | 14:30 | PR Newswire (US) | Synvista Therapeutics Announces Availability of Haptoglobin Genotyping Technology at The Annual Scientific Sessions of the Ameri | AMEX:SYI | Synvista Therapeutics, |
| 24/10/2008 | 18:10 | PR Newswire (US) | Synvista Therapeutics to Present at the 2008 BIO Investor Forum | AMEX:SYI | Synvista Therapeutics, |
| 10/10/2008 | 22:19 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | AMEX:SYI | Synvista Therapeutics, |
| 10/10/2008 | 22:07 | PR Newswire (US) | Synvista Therapeutics Appoints William Federici to its Board of Directors | AMEX:SYI | Synvista Therapeutics, |
| 29/09/2008 | 15:03 | PR Newswire (US) | Synvista Therapeutics Receives Approval to Begin Phase 2 Trial of Topical SYI-2074 in Psoriasis | AMEX:SYI | Synvista Therapeutics, |
| 17/09/2008 | 19:27 | PR Newswire (US) | Synvista Therapeutics Posts Letter to Stockholders on Web Site | AMEX:SYI | Synvista Therapeutics, |
| 15/09/2008 | 15:15 | PR Newswire (US) | Vista Partners Updates Coverage on Synvista Therapeutics, Inc. (Amex: SYI); Maintains $4.46 Target Price | AMEX:SYI | Synvista Therapeutics, |
| 11/09/2008 | 14:00 | PR Newswire (US) | Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patient | AMEX:SYI | Synvista Therapeutics, |
| 14/08/2008 | 15:29 | Edgar (US Regulatory) | Synvista Therapeutics, Inc. - Quarterly Report (10-Q) | AMEX:SYI | Synvista Therapeutics, |
| 25/07/2008 | 12:04 | Edgar (US Regulatory) | Synvista Therapeutics, Inc. - Current report filing (8-K) | AMEX:SYI | Synvista Therapeutics, |
| 24/07/2008 | 17:44 | Edgar (US Regulatory) | Synvista Therapeutics, Inc. - Statement of Changes in Beneficial Ownership (4) | AMEX:SYI | Synvista Therapeutics, |
| 06/06/2008 | 19:30 | PR Newswire (US) | Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Dise | AMEX:SYI | Synvista Therapeutics, |
| 04/06/2008 | 18:28 | Edgar (US Regulatory) | Synvista Therapeutics, Inc. - Additional Proxy Soliciting Materials (definitive) (DEFA14A) | AMEX:SYI | Synvista Therapeutics, |